All articles
GLP-1s for Athletes: Performance, Body Composition, and Recovery
Reading time:
9 min
Weight loss

Get expert guidance and a personalized care plan designed around you.
What We Don’t Know: Research Gaps
Honesty about limitations in current evidence is important for athletes making informed decisions.
We do not have large, well-controlled studies specifically in athletes or highly active populations. Most GLP-1 research enrolled sedentary or moderately active people with obesity. How elite athletes or serious recreational athletes respond may differ.
We do not have clear data on whether GLP-1 medications affect training adaptation, meaning whether you build muscle and improve fitness as effectively when taking these medications compared to when not taking them. Small studies suggest exercise may help, but rigorous trials are lacking.
We do not fully understand the long-term effects on muscle health, bone density, and functional capacity in athletic populations. Most trials followed participants for 68 to 176 weeks. Effects beyond this timeframe remain unknown.
We do not know optimal strategies for athletes who want to use these medications specifically for body composition changes rather than overall weight loss. The dosing, duration, and combination with training protocols have not been studied in athletic populations.
The Bottom Line for Athletes
GLP-1 medications offer powerful tools for weight and metabolic health management. For athletes who genuinely need weight loss for health reasons, these medications can be effective when combined with appropriate exercise and nutrition strategies.
However, athletes considering these medications primarily for body composition changes (rather than health-related weight loss) should understand that muscle preservation requires deliberate, intensive effort. Without prioritizing protein intake and resistance training, muscle loss will occur alongside fat loss.
The lack of VO2max improvement despite weight loss is concerning for endurance athletes whose performance depends heavily on cardiorespiratory fitness. Whether structured training programs can overcome this limitation remains to be definitively proven.
For strength and power athletes, the muscle mass loss (even if partially adaptive) may affect performance in sports where absolute strength, power output, or muscle mass itself matters for success.
Athletes using these medications should work closely with sports medicine providers, consider body composition tracking beyond just weight, maintain high protein intake even with reduced appetite, prioritize resistance training, and monitor performance metrics to catch excessive muscle loss early.
At Mochi Health, we provide comprehensive weight management care focused on overall health rather than athletic performance enhancement. Our registered dietitian nutritionists can help ensure you are meeting protein and nutritional needs during treatment. While our primary focus is health-related weight management, we understand that active individuals have specific concerns about preserving lean tissue. You can explore our approach to weight management at https://joinmochi.com/medications.
Check Your Eligibility
If you want to learn whether GLP-1 treatment is appropriate for your health needs and receive personalized guidance on nutrition and exercise during treatment, you can start by completing Mochi’s eligibility questionnaire. Check your eligibility.
References:
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038
Neeland, I. J., Linge, J., Tinsley, G. M., Yoshimi, K., Stennett, D., Mancio, J., Dahlqvist Leinhard, O., & Sattar, N. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 26(9), 3751-3766. https://doi.org/10.1111/dom.15728
Tinsley, G. M., Heymsfield, S. B., Xia, Z., Lofton, H., Huang, S. J., Voils, J., & Austin, G. L. (2024). Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. Obesity Science & Practice, 10(5), e70022. https://doi.org/10.1002/osp4.70022
Weeldreyer, N. R., Liu, Z., & Angadi, S. S. (2025). Cardiorespiratory fitness and weight loss with glucagon-like peptide-1 receptor agonist therapy: Challenges and opportunities. Obesity Reviews, 26(1), e13839. https://doi.org/10.1111/obr.13839
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
This article is for educational purposes only and should not be considered medical advice. GLP-1 medications are not approved for athletic performance enhancement. Consult with healthcare providers about whether these medications are appropriate for your individual health needs.
Share this post
Weight loss
More articles















